spacer
home > > autumn 2018 > theory to game changer
PUBLICATIONS

 

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

spacer

 
News and Press Releases

Ubiquigent Appoints Dr Sheelagh Frame, CSO, to Its Board of Directors

Dundee, UK, 24 October 2022: Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitylase (DUB) modulators as powerful new therapeutics, today announced the appointment of Dr Sheelagh Frame, Chief Scientific Officer (CSO), to the Company’s Board of Directors. The appointment comes at a key stage in the Company’s development with the growing importance of the DUBs in drug discovery and will help drive the progress of Ubiquigent’s internal portfolio of novel DUB modulators, associated drug discovery programmes and commercial services.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement